Status:
RECRUITING
Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
Lead Sponsor:
Evommune, Inc.
Conditions:
Chronic Spontaneous Urticaria
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).
Eligibility Criteria
Inclusion
- Confirmed CSU diagnosis for at least 3 months with an inadequate response to H1-antihistamines.
- Subjects who are taking H1-antihistamines must be on a stable regimen 4 weeks prior to Day 1 and while on study.
- Urticaria Activity Score (UAS7) equal to or greater than 16 at Day 1. UAS entries must be completed for a minimum of 4 out of the 7 days prior to Day 1.
Exclusion
- Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening, according to the Investigator's discretion.
- Use of certain medications.
- History of diseases with urticaria or angioedema symptoms, other than CSU and symptomatic dermographism.
- Significant medical history other than CSU, or any other condition which might interfere with the evaluation of CSU.
Key Trial Info
Start Date :
March 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT06873516
Start Date
March 20 2025
End Date
May 1 2026
Last Update
January 6 2026
Active Locations (53)
Enter a location and click search to find clinical trials sorted by distance.
1
Cahaba Dermatology Skin Health Center
Birmingham, Alabama, United States, 35244
2
Velocity Clinical Research, Mobile
Mobile, Alabama, United States, 36608
3
Center for Dermatology Clinical Research
Fremont, California, United States, 94538
4
Antelope Valley Clinical Trials
Lancaster, California, United States, 93534